Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme

Documenti analoghi

• Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases
  di: Tarita Murray‐Thomas, et al.
  Pubblicazione: (2025)
• Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
  di: Chenyang Shi, et al.
  Pubblicazione: (2024)
• Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence
  di: Alexandra A. Weinreich, et al.
  Pubblicazione: (2025)
• Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
  di: Ebaa Al Ozairi, et al.
  Pubblicazione: (2025)
• Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
  di: Jason M. Samuels, et al.
  Pubblicazione: (2025)